CheckMate 214 Exploratory Biomarker Analysis: Predicting Response to Nivolumab Plus Ipilimumab in Advanced RCC

Dr Eric Jonasch discusses advances in the care of patients with renal cell carcinoma in this on-demand webcast from Clinical Care Options (CCO)

Naomi B. Haas, MD
Program Director Eric Jonasch, MD
Program Director Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: January 26, 2023 Expired: January 25, 2024

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD, MS Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: November 14, 2022 Expired: November 13, 2023

Download these expert-selected slides on treatments for early and later-stage renal cell carcinoma.

Naomi B. Haas, MD
Program Director Eric Jonasch, MD
Program Director Katy Beckermann, MD, PhD Elizabeth R. Plimack, MD, MS Released: October 21, 2022

Phase III COSMIC-313: addition of cabozantinib to nivolumab plus ipilimumab in previously untreated patients with IMDC intermediate- or poor-risk advanced RCC, presented at ESMO 2022 and reported by Clinical Care Options (CCO)